OncoMatch/Clinical Trials/NCT07274852
A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Is NCT07274852 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Lutetium [177Lu] BL-ARC001 for lung cancer.
Treatment: Lutetium [177Lu] BL-ARC001 — This study is an open, multicenter, dose-escalation and cohort-expansion non-randomized phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of Lutetium \[177Lu\] BL-ARC001 in patients with locally advanced or metastatic solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Breast Carcinoma
Head and Neck Squamous Cell Carcinoma
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Organ function levels must meet the requirements
Kidney function
Organ function levels must meet the requirements
Liver function
Organ function levels must meet the requirements
Cardiac function
No severe cardiac dysfunction, left ventricular ejection fraction ≥50%; Prolonged QT interval, complete left bundle branch block, or third-degree atrioventricular block [excluded]
No severe cardiac dysfunction, left ventricular ejection fraction ≥50%; Organ function levels must meet the requirements; Coagulation function: INR ≤1.5, and APTT ≤1.5 × ULN; Urine protein ≤2+ or ≤1000mg/24h
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify